Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG1050 in Chronic Hepatitis B
NCT02428400Phase 1Completed
- Sponsor
- Transgene SA
- Start
- Oct 2015
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TG1050 with Placebo (2 arms). Primary endpoints: Safety and tolerability of TG1050 administered as single or multiple doses at Week 54 and Dosage of TG1050/placebo administration for investigation in Part B at Week 54. Started Oct 2015; status: completed.
02
Drugs
TG1050
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02428400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428400.